Platinum-based chemotherapy in triple-negative advanced breast cancer
Abstract
The purpose of this study was to evaluate the efficacy of platinum-based chemotherapy (PBC) versus conventional non-PBC regimens in a metastatic triple-negative breast cancer (TNBC) setting. We reviewed the electronic patient records of patients with confirmed metastatic TNBC at four major cancer centres in Canada. All patients were allocated into two groups based on type of chemotherapy received (PBC vs. non-PBC) and line of treatment (first-, second-, or third-line). The primary objective of this study was to evaluate the efficacy of PBC in metastatic TNBC in terms of median duration of overall survival (OS) from diagnosis of distant metastatic disease and compare it with the efficacy of conventional non-platinum-based chemotherapy in metastatic TNBC after controlling for known prognostic factors. A total of 153 metastatic TNBC patients were identified, 58 treated with PBC and 95 with non-PBC. The median time in first-line PBC versus non-PBC was not different between the two groups (2 vs. 2 months, p = 0.9), the median time on treatment in second and third-line therapy was longer for the PBC group compared to the conventional treated group (4 vs. 1 months, p = 0.004; 4 vs. 0.5 months, p = 0.004, respectively). Patients who received PBC had a longer OS compared to those managed conventionally (14.5 vs. 10 months, p = 0.041). This study evaluates the survival outcomes in a homogenous group of TNBC metastatic patients treated with or without PBC. Our results confirmed our hypothesis of a better OS among PBC-treated TNBC patients compared to conventionally managed TNBC patients. Currently ongoing Phase III trials assessing the benefit of PBC versus other chemotherapeutic regimens in advanced TNBC will help define the role of these agents for the management of this breast cancer subtype.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical studies indicate that platinum-based therapy can provide enhanced efficacy in triple-negative breast cancer.
“Clinical studies have indicated that platinum-based therapy can provide enhanced efficacy in TNBC (4, 5).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [4]
Ongoing clinical trials for metastatic TNBC include platinum agents in their treatment regimens.
“Furthermore, ongoing clinical trials for metastatic TNBC are including platinum agents in their treatment regimens (4, 36–38).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [4]
Cites
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592 · see citing works
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · see citing works
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N. K., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J. J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,889 · see citing works
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,651 · see citing works
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,134 · see citing works
Haffty, B. G., Yang, Q., Reiß, M., Kearney, T. J., Higgins, S. A., Weidhaas, J. B., Harris, L. N., Hait, W., & Toppmeyer, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5664 · Cited by 1,085 · see citing works
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 857 · see citing works
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817 · see citing works
Lin, N., Claus, E. B., Sohl, J. J., Razzak, A. R., Arnaout, A., & Winer, E. P. (2008) · Cancer · doi:10.1002/cncr.23930 · Cited by 735 · see citing works
Basal-like breast cancer and the BRCA1 phenotype
Turner, N. C., & Reis-Filho, J. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209876 · Cited by 481 · see citing works
Kassam, F., Enright, K. A., Dent, R. A., Dranitsaris, G., Myers, J., Flynn, C., Fralick, M., Kumar, R. D., & Clemons, M. J. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.005 · Cited by 474 · see citing works
O’Shaughnessy, J., Schwartzberg, L. S., Danso, M. A., Rugo, H. S., Miller, K. D., Yardley, D. A., Carlson, R. W., Finn, R., Charpentier, E., Freese, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.1007 · Cited by 244 · see citing works
Platinum-based chemotherapy in triple-negative breast cancer
Sirohi, B., Arnedos, M., Popat, S., Ashley, S. E., Nerurkar, A. Y., Walsh, G., Johnston, S. R. D., & Smith, I. E. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn395 · Cited by 220 · see citing works
Platinum-based chemotherapy in metastatic breast cancer: current status
Decatris, M. P., Sundar, S., & O'Byrne, K. J. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00139-7 · Cited by 212 · see citing works
Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies
Toft, D. J., & Cryns, V. L. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0164 · Cited by 160 · see citing works
Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy
Peddi, P. F., Ellis, M. J., & Ma, C. X. (2011) · International Journal of Breast Cancer · doi:10.1155/2012/217185 · Cited by 127 · see citing works
Staudacher, L., Cottu, P. H., Dieras, V. C., Vincent‐Salomon, A., Guilhaume, M. N., Escalup, L., Dorval, T., Beuzeboc, P., Mignot, L., & Pierga, J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq461 · Cited by 87 · see citing works
Hurley, J., Reis, I. M., Rodgers, S. E., Gomez-Fernandez, C., Wright, J., Leone, J. P., Larrieu, R., & Pegram, M. D. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2497-y · Cited by 83 · see citing works
Koshy, N. V., Quispe, D., Shi, R., Mansour, R. P., & Burton, G. V. (2010) · The Breast · doi:10.1016/j.breast.2010.02.003 · Cited by 79 · see citing works
Uhm, J. E., Park, Y. H., Yi, S. Y., Cho, E. Y., Choi, Y., Lee, S. J., Park, M. J., Lee, S., Jun, H. J., Ahn, J. S., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24090 · Cited by 72 · see citing works
von Minckwitz, G., Schneeweiß, A., Salat, C., Rezai, M., Zahm, D. M., Klare, P., Blohmer, J., Tesch, H., Khandan, F., Jud, S. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.1004 · Cited by 55 · see citing works
Baselga, J. M., Stemmer, S. M., Pêgo, A., Chan, A., Goeminne, J.-C., Graas, M. P., Kennedy, J. F., Gil, E. C., Zubel, A., Groos, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-pd01-01 · Cited by 49 · see citing works
Isakoff, S. J., Goss, P. E., Mayer, E. L., Traina, T., Carey, L., Krag, K. J., Rugo, H. S., Liu, M., Stearns, V., Come, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.1025 · Cited by 35 · see citing works
Emerging Trends in the Treatment of Triple-Negative Breast Cancer in Canada: A Survey
Verma, S., Provencher, L., & Dent, R. A. (2011) · Current Oncology · doi:10.3747/co.v18i4.913 · Cited by 26 · see citing works
Bhattacharyya, G. S., Basu, S., Agarwal, V., Malhotra, H., Pareekh, P., Babu, K. G., & Aggarwala, D. (2009) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(09)72076-2 · Cited by 23 · see citing works
Cameron, D., Brown, J. M., Dent, R. A., Jackisch, C., Mackey, J. R., Pivot, X. B., Steger, G. G., Suter, T., Toi, M., Parmar, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-s6-5 · Cited by 11 · see citing works
Wang, Z., Hu, X., Chen, L., Wang, J., Wang, H., Wang, L., Liu, G., Hu, Z., Wu, J., & Zhimin, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.1100 · Cited by 10 · see citing works
Khalaf, D. J., Hilton, J. F., Clemons, M. J., Azoulay, L., Yin, H., Vandermeer, L., Dent, S. F., Hopkins, S. P., & Bouganim, N. (2014) · Oncology Letters · doi:10.3892/ol.2014.1782 · Cited by 9 · see citing works
Kim, T. H., Lee, H., Han, S., Oh, D.-Y., Im, S., & Bang, Y.-J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.1071 · Cited by 5 · see citing works
Kimman, M., Dirksen, C. D., Falger, P. R. J., Voogd, A. C., Kessels, A. G. H., Gijsen, B., MEYENFELDT, M. F. V., Hupperets, P. S. G. J., Lambin, P., & Boersma, L. J. (2009) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(09)72075-0 · Cited by 4 · see citing works
Fan, Y., Xu, B., Yuan, P., Wang, J., Ma, F., Ding, X., Zhang, P., Li, Q., & Cai, R. (2011) · Cancer Research · doi:10.1158/0008-5472.sabcs11-p5-19-04 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics
Anders, C. K., Abramson, V. G., Tan, T. J., & Dent, R. A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159135 · Cited by 160 · see citing works
Liang, D. H., Choi, D. S., Ensor, J., Kaipparettu, B. A., Bass, B. L., & Chang, J. C. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.002 · Cited by 136 · see citing works
Changing Treatment Paradigms in Metastatic Breast Cancer
Santa-Maria, C. A., & Gradishar, W. J. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1198 · Cited by 104 · see citing works
Balsa, L. M., Ruiz, M. C., de la Parra, L. S. M., Baran, E. J., & León, I. E. (2019) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2019.110975 · Cited by 67 · see citing works
miR‐381 overcomes cisplatin resistance in breast cancer by targeting MDR1
Yi, D., Xu, L., Wang, R., Lu, X., & Sang, J. (2018) · Cell Biology International · doi:10.1002/cbin.11071 · Cited by 58 · see citing works
SNHG15 Contributes To Cisplatin Resistance In Breast Cancer Through Sponging miR-381
Mi, H., Wang, X., Wang, F., Li, L., Zhu, M., Wang, N., Xiong, Y., & Gu, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s223321 · Cited by 50 · see citing works
Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy
Jin, J., Zhang, W., Ji, W., Yang, F., & Guan, X. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1323582 · Cited by 43 · see citing works
Tonsing-Carter, E., Bailey, B. J., Saadatzadeh, M. R., Ding, J., Wang, H., Sinn, A. L., Peterman, K. M., Spragins, T. K., Silver, J. M., Sprouse, A. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0237 · Cited by 42 · see citing works
Platinum-based chemotherapy in triple-negative breast cancer
Guan, X., Ma, F., Fan, Y., Zhu, W., Hong, R., & Xu, B. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000260 · Cited by 35 · see citing works
Dou, D., Ge, X. Q., Wang, X., Xu, X., Zhang, Z., Jingjing, S., Cao, Z., Gu, Y., & Han, M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s214104 · Cited by 33 · see citing works
Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer
Garmpis, N., Damaskos, C., Garmpi, A., Nikolettos, K., Dimitroulis, D., Diamantis, E., Farmaki, P., Patsouras, A., Voutyritsa, E., Syllaios, A., et al. (2020) · In Vivo · doi:10.21873/invivo.11965 · Cited by 34 · see citing works
Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines
Joy, A. A., Ghosh, M., Fernandes, R., & Clemons, M. J. (2015) · Current Oncology · doi:10.3747/co.22.2360 · Cited by 20 · see citing works
Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer
Locatelli, M., Curigliano, G., & Eniu, A. E. (2017) · Breast Care · doi:10.1159/000478087 · Cited by 18 · see citing works
Gari, H. H., Degala, G. D., Lucia, M. S., & Lambert, J. R. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.50 · Cited by 17 · see citing works
Abou‐Fadel, J., Bhalli, M., Grajeda, B. I., & Zhang, J. (2022) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2021.0221 · Cited by 16 · see citing works
Chen, Y., Guan, Y., Wang, J., Ma, F., Luo, Y., Chen, S., Zhang, P., Li, Q., Cai, R., Li, Q., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33175 · Cited by 16 · see citing works
li, M., Fan, Y., Li, Q., Zhang, P., Yuan, P., Ma, F., Wang, J., Luo, Y., Cai, R., Chen, S., et al. (2015) · Medicine · doi:10.1097/md.0000000000001928 · Cited by 15 · see citing works
Case report of long-term survival with metastatic triple-negative breast carcinoma
Chue, B. M.-F., & Course, B. D. L. (2019) · Medicine · doi:10.1097/md.0000000000015302 · Cited by 15 · see citing works
Palomba, G., Atzori, F., Budroni, M., Ombra, M. N., Cossu, A., Sini, M. C., Pusceddu, V., Massidda, B., Frau, B., Notari, F., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0272-4 · Cited by 14 · see citing works
Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis
Tian, M., Zhong, Y., Zhou, F., Xie, C., Zhou, Y., & Liao, Z. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.518 · Cited by 13 · see citing works
Gari, H. H., Gearheart, C. M., Fosmire, S. P., DeGala, G. D., Fan, Z., Torkko, K. C., Edgerton, S. M., Lucia, M. S., Ray, R., Thor, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7462 · Cited by 11 · see citing works
Liu, J., XIAO, Y., Wei, W., Guo, J., Liu, Y., HUANG, X.-H., Rong-xia, Z., WU, Y.-J., & Zhou, J. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2489 · Cited by 10 · see citing works
Lu, F., Hou, Y., Chen, Z., Jiang, J., He, X., Xia, Y., Cao, K., Chang, L., & Li, W. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211016369 · Cited by 10 · see citing works
Jacobs, C. M., Clemons, M. J., Mazzarello, S., Hutton, B., Joy, A. A., Brackstone, M., Freedman, O. C., Vandermeer, L., Ibrahim, M. F. K., Fergusson, D. A., et al. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3580-4 · Cited by 8 · see citing works
Dong, L., Wu, N., Wang, S., Cheng, Y., Han, L., Zhao, J., Long, X., Mu, K., Li, M., Wei, L., et al. (2018) · Human Mutation · doi:10.1002/humu.23597 · Cited by 8 · see citing works
Can we cure stage IV triple-negative breast carcinoma?
Chue, B. M.-F., & Course, B. D. L. (2019) · Medicine · doi:10.1097/md.0000000000017251 · Cited by 5 · see citing works
Abou‐Fadel, J., Bhalli, M., Grajeda, B. I., & Zhang, J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.13.460145 · Cited by 4 · see citing works
The role of long non-coding RNAs in breast cancer drug resistance: a comprehensive review
Xu, Y., Ma, J., Ding, C., Liang, W., Zeng, Q., & Lv, B. (2025) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2025.67 · Cited by 3 · see citing works
Hilton, J. F., Stober, C., Mazzarello, S., Vandermeer, L., Fergusson, D. A., Hutton, B., & Clemons, M. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199297 · Cited by 3 · see citing works
Modulation of the Mdm2 signaling axis sensitizes triple-negative breast cancer cells to carboplatin
Tonsing-Carter, E. Y. (2014) · ProQuest Demo Repository · doi:10.7912/c2/308
Systemic Treatment of HER2-Negative Metastatic Breast Cancer
Bayraktar, S., & Aydıner, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-96947-3_22
Treatment of HER2-Negative Metastatic Breast Cancer: Chemotherapy
Bayraktar, S., & Aydıner, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-16792-9_31
Moşoiu, S., Gales, L. N., & Ciochir, D. (2021) · Oncolog-Hematolog ro · doi:10.26416/onhe.5.1.2021.4569
- Authors
- Villarreal-Garza, C., Khalaf, D., Bouganim, N., Clemons, M., Peña-Curiel, O., Baez-Revueltas, B., Kiss, A., Kassam, F., Enright, K., Verma, S., Pritchard, K., Myers, J., & Dent, R.
- Affiliations
- Instituto Nacional de Cancerología (MX)
- University of Ottawa (CA)
- Instituto Tecnológico Autónomo de México (MX)
- Sunnybrook Health Science Centre (CA)
- Princess Margaret Cancer Centre (CA)
- Trillium Health Centre (CA)
- Corresponding author
- Dent, Rebecca
- ORCID
- Venue
- Breast Cancer Research and Treatment
- Published
- 2014-07-08
- Volume
- 146
- Issue
- 3
- Pages
- 567-572
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2034849620
- Cited by
- 33
- References
- 31
- Citations by year
- 2025: 1 · 2022: 1 · 2021: 3 · 2020: 3 · 2019: 5 · 2018: 4 · 2017: 3 · 2016: 4 · 2015: 7 · 2014: 2
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-03-26)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- platinum-based chemotherapy, triple-negative breast cancer, metastatic breast cancer, overall survival, second-line therapy, third-line therapy, first-line therapy, treatment duration, prognostic factors
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Canada, Female, Humans, Neoplasm Metastasis, Neoplasm Staging, Platinum, Treatment Outcome, Disease-Free Survival, Electronic Health Records, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
